We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exploratory Study of Relationships Between Malodor and Urine Metabolomics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02683876
Recruitment Status : Active, not recruiting
First Posted : February 17, 2016
Last Update Posted : October 4, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to identify metabolic signatures associated with malodor conditions. The investigators will perform state-of-the art metabolomics tests and bioinformatic data mining to explore if conditions leading to malodor can be screened by metabolomic profiling of urine samples.

Condition or disease
Nutritional and Metabolic Diseases

Detailed Description:
In this study, metabolite profiling analysis will be carried out on urine samples of individuals with malodor conditions related to metabolism inefficiencies. Metabolic profiles will be identified using the metabolomics equipment located in the NMR, HPLC and MS facilities of the Metabolomics Innovation Centre (TMIC). Multivariate statistical analyses will be used, as well as other approaches to mine complex data from heterogeneous sources.

Study Design

Study Type : Observational
Actual Enrollment : 54 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies
Actual Study Start Date : February 2016
Primary Completion Date : August 30, 2017
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Subjects with malodor
individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
Healthy control
individuals not complaining of uncontrollable or unpredictable malodor episodes


Outcome Measures

Primary Outcome Measures :
  1. Differences in metabolite concentrations measured by mass spectrometry, comparing urine samples from individuals with malodor issues, and age-matched healthy controls. [ Time Frame: ten months ]
    The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor


Secondary Outcome Measures :
  1. Correlations between urine biomarkers and frequency/severity of malodor symptoms (questionnaires) [ Time Frame: one year ]
    The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from non-severe malodor symptoms


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
individuals complaining of uncontrollable episodes of malodor suspected to be caused by inefficient body metabolism
Criteria

Inclusion Criteria:

  • 18 years or older
  • unpredictable and uncontrollable episodes of malodor
  • willing and able to ship a urine sample (in the kit provided) by an overnight courier to Edmonton, Alberta, Canada
  • good general health

Exclusion Criteria:

  • serious medical conditions that require treatment
  • conditions that, in the opinion of the investigator, would prevent participation
  • under the age of 18
  • elect not to participate in the study
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02683876


Locations
United States, Florida
MeBO Research
Miami, Florida, United States, 33175
Canada, Alberta
The Metabolomics Innovation Centre
Edmonton, Alberta, Canada, T6G 2E9
Sponsors and Collaborators
Mebo Research, Inc.
University of Alberta
Investigators
Principal Investigator: David Wishart, PhD The Metabolomics Innovation Centre (TMIC)
Principal Investigator: Irene Gabashvili, PhD MeBo Research
More Information

Additional Information:
Publications:
Responsible Party: Mebo Research, Inc.
ClinicalTrials.gov Identifier: NCT02683876     History of Changes
Other Study ID Numbers: 201505010014MEBO
First Posted: February 17, 2016    Key Record Dates
Last Update Posted: October 4, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: to prevent risks of re-identification.

Keywords provided by Mebo Research, Inc.:
body odor, malodor, halitosis

Additional relevant MeSH terms:
Metabolic Diseases